$0.15
−1.96%Sep 29, 2026, 12:03 UTC
Silexion Therapeutics Corp. entered definitive agreements for the immediate exercise of outstanding series E warrants to purchase up to 3,216,928 ordinary shares at a reduced exercise price of $0.2603 per share, expecting gross proceeds of about $837,366.36.
Source:Sep 28, 2026, 08:52 UTC
Sileptai (Shanghai) Biopharmaceutical Technology Co., Ltd. completed a Series A financing of over USD 50 million, led by Decheng Capital, with Huatai GenScript Fund and China Merchants Venture Capital participating, and existing shareholders Morningside Venture Capital, Shunwei Capital, and Qianju Capital continuing to add support.
Source:Sep 25, 2026, 20:37 UTC
Silexion Therapeutics Corp received a NASDAQ notice dated September 25, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), and requested a hearing.
Aug 21, 2026, 00:00 UTC
Silexion Therapeutics Corp received a notice from Nasdaq on August 18, 2026, stating it no longer complies with the minimum shareholders' equity requirement under Rule 5550(b)(1), and the company plans to appeal before the Nasdaq Hearings Panel.
Aug 12, 2026, 00:01 UTC
Silexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares and series E warrants at a combined price of $0.65 per share, expected to close on August 13, 2026.
Source:Jun 23, 2026, 12:40 UTC
Silexion Therapeutics received approval from Germany's BfArM and a positive ethics committee opinion to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.